US4504586AExpiredUtility

Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1

84
Assignee: AMGENPriority: Feb 3, 1983Filed: Feb 3, 1983Granted: Mar 12, 1985
Est. expiryFeb 3, 2003(expired)· nominal 20-yr term from priority
Y10S530/809Y10S530/828C07K 16/243C07K 14/53Y10S930/145
84
PatentIndex Score
49
Cited by
53
References
21
Claims

Abstract

Murine-derived hybridoma tumor cell lines and monoclonal anti-Colony Stimulating Factor Subclass Number 1 antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of natural Colony Stimulating Factor Subclass Number 1 and for quantitative detection of colony Stimulating Factor Subclass Number 1 in fluid samples.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A murine-derived hybridoma cell line capable of producing in the medium of its growth a monoclonal antibody capable of specifically binding with Colony Stimulating Factor Subclass Number 1 in an antigen/antibody complex. 
     
     
       2. A hybridoma cell line according to claim 1 which is ATCC No. HB8207. 
     
     
       3. A hybridoma cell line according to claim 1 which is ATCC No. HB8208. 
     
     
       4. A monoclonal antibody produced by a hybridoma cell line according to claim 1. 
     
     
       5. A monoclonal antibody produced by hybridoma cell line ATCC No. HB8207 according to claim 2. 
     
     
       6. A monoclonal antibody produced by hybridoma cell line ATCC No. HB8208 according to claim 3. 
     
     
       7. In an immunological procedure for isolation of biologically active Colony Stimulating Factor Subclass Number 1 from a biological fluid on the basis of a selective immunological reaction with an antibody specific for Colony Stimulating Factor Subclass Number 1, the improvement comprising: employing the monoclonal antibody of claim 4 or 5 or 6 as said specific antibody.   
     
     
       8. The improvement of claim 7 wherein said fluid is a human fluid. 
     
     
       9. The improvement of claim 7 wherein said fluid is a member of the group comprising whole blood, serum and urine. 
     
     
       10. In an immunological procedure for the quantitative detection of Colony Stimulating Factor Subclass Number 1 in a biological fluid on the basis of a selective immunological reaction with an antibody specific for Colony Stimulating Factor Subclass Number 1, the improvement comprising: employing the monoclonal antibody of claim 4 or 5 or 6 as said specific antibody.   
     
     
       11. The improvement of claim 10 wherein said fluid is a human fluid. 
     
     
       12. The improvement of claim 10 wherein said fluid is a member of the group comprising whole blood, serum and urine. 
     
     
       13. The improvement of claim 10 wherein said immunological procedure is a radioimmunobinding assay. 
     
     
       14. A monoclonal antibody produced by a murine-derived hybridoma cell line according to claim 1, said antibody capable of specifically binding in an antigen-antibody complex with that portion of a polypeptide which consists essentially of an amino acid sequence comprising: NHR-Asp-Val-Glu-Phe-Asp-COR', wherein R and R' are the same or different amino acid residues or R is hydrogen or R' is a hydroxyl group. 
     
     
       15. The product according to claim 14 wherein the amino acid sequence of the polypeptide comprises: RNH-Leu-Pro-Pro-Asp-Val-Glu-Phe-Asp-Arg-Pro-Phe-Leu-Arg-COR', wherein R and R' are the same or different amino acid residues or R is hydrogen or R' is a hydroxyl group. 
     
     
       16. The product of claim 15 wherein R is selected from the group consisting of serine, histidine, and glutamic acid and R' is cystein. 
     
     
       17. An immunological assay for quantitative detection of Colony Stimulating Factor Subclass Number 1 in a biological fluid sample comprising the steps of: (1) contacting said fluid with a first, immobilized, antibody which reacts with a first antigenic determinant of Colony Stimulating Factor Subclass Number 1 in said fluid to form an immunological complex of Colony Stimulating Factor Subclass Number 1 and said first antibody;   (2) contacting the complex formed in step (1) with a second antibody which reacts with an antigenic determinant of Colony Stimulating Factor Subclass Number 1 other than said first antigenic determinant, to form an immunological complex of Colony Stimulating Factor Subclass Number 1 and said second antibody; and   (3) quantifying the amount of said second antibody bound to said immunological complex formed in step (2).   
     
     
       18. The assay according to claim 17 wherein said first antibody is a monoclonal antibody produced by a murine-derived hybridoma cell line capable of producing in the medium of its growth a monoclonal antibody capable of specifically binding with Colony Stimulating Factor Subclass Number 1 in an antigen/antibody complex and said second antibody is selected from the group consisting of a serum-derived polyvalent antibody to Colony Stimulating Factor Subclass Number 1, or a monoclonal antibody produced by hybridoma cell line ATCC No. HB8207, or a monoclonal antibody produced by hybridoma cell line ATCC No. HB8208 or a monoclonal antibody produced by a murine-derived hybridoma cell line capable of producing in the medium of its growth a monoclonal antibody capable of specifically binding with Colony Stimulating Factor Subclass Number 1 in an antigen/antibody complex, said antibody capable of specifically binding in an antigen/antibody complex with that portion of a polypeptide which consists essentially of an amino acid sequence comprising: NHR-Asp-Val-Glu-Phe-Asp-COR', wherein R and R' are the same or different amino acid residues or R is hydrogen or R' is a hydroxyl group. 
     
     
       19. The assay according to claim 17 wherein said first antibody is a monoclonal antibody produced by hybridoma cell line ATCC No. HB8207, and said second antibody is selected from the group consisting of a serum-derived polyvalent antibody to Colony Stimulating Factor Subclass Number 1, or a monoclonal antibody produced by a murine-derived hybridoma cell line capable of producing in the medium of its growth a monoclonal antibody capable of specifically binding with Colony Stimulating Factor Subclass Number 1 in an antigen/antibody complex, or a monoclonal antibody produced by hybridoma cell line ATCC No. HB8208, or a monoclonal antibody produced by a murine-derived hybridoma cell line capable of producing in the medium of its growth a monoclonal antibody capable of specifically binding with Colony Stimulating Factor Subclass Number 1 in an antigen/antibody complex, said antibody capable of specifically binding in an antigen/antibody complex with that portion of a polypeptide which consists essentially of an amino acid sequence comprising: NHR-Asp-Val-Glu-Phe-Asp-COR', wherein R and R' are the same or different amino acid residues or R is hydrogen or R' is a hydroxyl group. 
     
     
       20. The assay according to claim 17 wherein said first antibody is a monoclonal antibody produced by hybridoma cell line ATCC No. HB8208, and said second antibody is selected from the group consisting of a serum-derived polyvalent antibody to Colony Stimulating Factor Subclass Number 1, or a monoclonal antibody produced by a murine-derived hybridoma cell line capable of producing in the medium of its growth a monoclonal antibody capable of specifically binding with Colony Stimulating Factor Subclass Number 1 in an antigen/antibody complex, or a monoclonal antibody produced by hybridoma cell line ATCC No. HB8207 or a monoclonal antibody produced by a murine-derived hybridoma cell line capable of producing in the medium of its growth a monoclonal antibody capable of specifically binding with Colony Stimulating Factor Subclass Number 1 in an antigen/antibody complex, said antibody capable of specifically binding in an antigen/antibody complex with that portion of a polypeptide which consists essentially of an amino acid sequence comprising: NHR-Asp-Val-Glu-Phe-Asp-COR', wherein R and R' are the same or different amino acid residues or R is hydrogen or R' is a hydroxyl group. 
     
     
       21. The assay according to claim 17 wherein said first antibody is a monoclonal antibody produced by a murine-derived hybridoma cell line capable of producing in the medium of its growth a monoclonal antibody capable of specifically binding with Colony Stimulating Factor Subclass Number 1 in an antigen/antibody complex, said antibody capable of specifically binding in an antigen/antibody complex with that portion of a polypeptide which consists essentially of an amino acid sequence comprising: NHR-Asp-Val-Glu-Phe-Asp-COR', wherein R and R' are the same or different amino acid residues or R is hydrogen or R' is a hydroxyl group, and said second antibody is selected from the group consisting of a serum-derived polyvalent antibody to Colony Stimulating Factor Subclass Number 1, or a monoclonal antibody produced by a murine-derived hybridoma cell line capable of producing in the medium of its growth a monoclonal antibody capable of specifically binding with Colony Stimulating Factor Subclass Number 1 in an antigen/antibody complex, or a monoclonal antibody produced by hybridoma cell line ATCC No. HB8207 or a monoclonal antibody produced by hybridoma cell line ATCC No. HB8208.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.